Prokidney Corp. ((PROK)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Prokidney Corp. has recently completed a Phase 2 clinical study titled ‘A Phase 2, Randomized, Open-Labeled, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)’. The study aimed to evaluate the safety, efficacy, and durability of REACT injections in improving renal function in patients with diabetes and chronic kidney disease. This study is significant as it explores a novel therapeutic approach for a condition with limited treatment options.
The intervention tested in this study is the Renal Autologous Cell Therapy (REACT), a biological treatment involving autologous selected renal cells. The therapy is designed to be delivered percutaneously into the kidneys to potentially slow or reverse the progression of renal disease.
The study employed a randomized, parallel intervention model without masking, focusing on treatment as its primary purpose. Participants were divided into two cohorts, receiving either one or two REACT injections, with follow-up periods extending up to 18 months to assess long-term effects.
The study commenced on July 27, 2021, and was recently updated on June 24, 2025. These dates are crucial as they mark the timeline of the study’s progression and the latest insights into its findings.
This update could positively influence Prokidney Corp.’s stock performance, as successful results may boost investor confidence and position the company as a leader in innovative kidney disease treatments. Competitors in the renal treatment space may face increased pressure to advance their own research and development efforts.
The study is now completed, with further information available on the ClinicalTrials portal.